Johnson & Johnson vs Pfizer Inc., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where JNJ and PFE diverge most: on ev/ebitda, JNJ reads 329.9 and PFE reads 30.6; on p/b, JNJ reads 7.74 and PFE reads 1.53. The rest of the comparable metrics sit closer together. What JNJ's price implies is a demanding bet versus history and the cohort (segment-resolved basis). What PFE's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | JNJ | PFE |
|---|---|---|
| Price | $256.93 | $24.19 |
| Market cap | $628.2B | $138.6B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | -4.3% |
| P/E | 29.8 | 18.5 |
| P/B | 7.74 | 1.53 |
| P/S | 6.52 | 2.19 |
| EV/EBITDA | 329.9 | 30.6 |
| Revenue growth | +7.9% | +2.1% |
| Gross margin | 66.3% | — |
| Net margin | 21.8% | 11.8% |
| Return on equity | 25.9% | 8.3% |
| Return on assets | 10.5% | 3.6% |
| FCF yield | 2.8% | 6.8% |
| Dividend yield | 2.0% | 7.1% |
| Debt / equity | 0.68 | 0.71 |
| Current ratio | 1.03 | 1.25 |
| Altman Z (solvency) | 4.82 | 1.85 |
| Piotroski F (quality) | 5 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.